| Current Price | $56.41 | Mkt Cap | $92.0B |
|---|---|---|---|
| Open | $56.15 | P/E Ratio | 16.32 |
| Prev. Close | $56.48 | Div. (Yield) | $1.64 (2.9%) |
| Daily Range | $55.30 - $56.50 | Volume | 90,857,792 |
| 52-Wk Range | $42.49 - $59.17 | Avg. Daily Vol. | 12,799,698 |
Bristol-Myers Squibb discovers, develops, licenses, makes, and sells pharmaceuticals, with particular success in cardiovascular treatments.
| Current Price | $56.41 | Mkt Cap | $92.0B |
|---|---|---|---|
| Open | $56.15 | P/E Ratio | 16.32 |
| Prev. Close | $56.48 | Div. (Yield) | $1.64 (2.9%) |
| Daily Range | $55.30 - $56.50 | Volume | 90,857,792 |
| 52-Wk Range | $42.49 - $59.17 | Avg. Daily Vol. | 12,799,698 |
The best Bull and Bear pitches based on recency and number of recommendations.
Non-cyclical, at least to the economy, which does well in a Bear Market (which we now are in).
Strong pipeline and a culture that wants to innovate. Strong focus on patients. Leadership seems to struggle with launching products and being competitive out the door. Long term will either find BMY on strong footing or acquired.
Read the most recent pitches from players about BMY.
Recs
NewCap
(< 20)
Submitted: 9/26/2019 3:53:42 PM :
Start Price:
$49.44
NYSE:BMY Score:
+9.58
The prospective high growth for the next fiscal years is among the main assets of the company
The company is in a robust financial situation considering its net cash and margin position.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
For the past twelve months, EPS forecast has been revised upwards.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock
Recs
JohnnyMac28
(67.55)
Submitted: 8/14/2019 12:03:40 PM :
Start Price:
$45.87
NYSE:BMY Score:
+14.08
healthcare play
Recs
TMFBigFrog
(92.95)
Submitted: 7/18/2019 11:43:58 PM :
Start Price:
$43.82
NYSE:BMY Score:
+25.14
Looks reasonably cheap after adjusting for Celgene acquisition.
Find the members with the highest scoring picks in BMY.
d3lta4ce (30.84) Score: +255.45
The Score Leader is the player with the highest score across all their picks in BMY.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| 99FE905 | 20.93 | 6/20/2008 |
|
5Y | $12.88 | +338.10% | +141.97% | +196.13 | 0 Comment | |
| tkaskmaster | 47.94 | 6/23/2008 |
|
3M | $12.89 | +337.65% | +142.71% | +194.93 | 0 Comment | |
| Nacho2k | 80.41 | 6/13/2008 |
|
3Y | $13.06 | +331.95% | +137.10% | +194.84 | 0 Comment | |
| SandmanKy | 84.20 |
|
|
5Y | $12.99 | +334.34% | +139.55% | +194.78 | 1 Comment | |
| tylerfu | 65.98 | 6/13/2008 |
|
5Y | $12.99 | +334.34% | +139.55% | +194.78 | 0 Comment | |
| tnovosad | < 20 | 6/13/2008 |
|
NS | $13.07 | +331.52% | +136.88% | +194.64 | 0 Comment | |
| snowape | 75.93 | 6/18/2008 |
|
3Y | $12.98 | +334.45% | +140.50% | +193.95 | 1 Comment | |
| cyberDEAD | < 20 | 6/20/2008 |
|
1Y | $12.97 | +335.01% | +141.10% | +193.91 | 0 Comment | |
| CLF65 | 34.91 |
|
|
1Y | $12.88 | +338.10% | +144.41% | +193.69 | 0 Comment | |
| bigbird0459 | < 20 | 6/11/2008 |
|
NS | $13.05 | +332.16% | +138.54% | +193.62 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
